Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Assess the Safety, Tolerability, PD and PK of RLS-0071 in Healthy Adult Subjects After Challenge With Inhaled Lipopolysaccharide (LPS)

NCT05351671 is registered in ClinicalTrials.gov with ReAlta Life Sciences, Inc. as lead sponsor.

NCT NCT05351671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05351671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Assess the Safety, Tolerability, PD and PK of RLS-0071 in Healthy Adult Subjects After Challenge With Inhaled Lipopolysaccharide (LPS)
Lead sponsor
ReAlta Life Sciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 23, 2022
Completion date
September 21, 2022
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy